Optimization and characterization of candidate strain for coxsackievirus A16 inactivated vaccine

Viruses

Volumn 7, Issue 7, 2015, Pages 3891-3909

  Li, Jingliang ^a   Liu, Guanchen ^a   Liu, Xin ^a   Yang, Jiaxin ^a   Chang, Junliang ^a   Zhang, Wenyan ^a   Yu, Xiao Fang ^a,b  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Coxsackievirus A16; HFMD; Inactivated vaccine; Vaccine candidate strain

Indexed keywords

COMPLEMENTARY DNA; COXSACKIEVIRUS A16 VACCINE; INACTIVATED VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ARTICLE; CONTROLLED STUDY; COXSACKIEVIRUS A16; ELECTRON MICROSCOPY; FOOT AND MOUTH DISEASE; GENETIC STABILITY; IMMUNOGENICITY; NONHUMAN; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SEQUENCE ANALYSIS; VACCINE PRODUCTION; VERO CELL LINE; VIROGENESIS; VIRUS CHARACTERIZATION; VIRUS GENOME; VIRUS NEUTRALIZATION; VIRUS STRAIN; WESTERN BLOTTING; ANIMAL; CHLOROCEBUS AETHIOPS; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS A; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; MOUSE; VIROLOGY;

COXSACKIEVIRUS; HUMAN ENTEROVIRUS 71;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS A, HUMAN; FEMALE; HUMANS; MICE; MICE, INBRED ICR; VACCINES, INACTIVATED; VERO CELLS; VIRAL VACCINES;

EID: 84937437583     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7072803     Document Type: Article

References (37)

1. McMinn, P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev. 2002, 26, 91–107. [CrossRef] [PubMed]
2. Zhu, F.C.; Liang, Z.L.; Meng, F.Y.; Zeng, Y.; Mao, Q.Y.; Chu, K.; Song, X.F.; Yao, X.; Li, J.X.; Ji, H., et al. Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants. PLoS ONE 2012, 7, e37206. [CrossRef] [PubMed]
3. Zhu, F.C.; Liang, Z.L.; Li, X.L.; Ge, H.M.; Meng, F.Y.; Mao, Q.Y.; Zhang, Y.T.; Hu, Y.M.; Zhang, Z.Y.; Li, J.X., et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: A randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2013, 381, 1037–1045. [CrossRef]
4. Zhang, Y.; Tan, X.J.; Wang, H.Y.; Yan, D.M.; Zhu, S.L.; Wang, D.Y.; Ji, F.; Wang, X.J.; Gao, Y.J.; Chen, L., et al. An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J. Clin. Virol. 2009, 44, 262–267. [CrossRef] [PubMed]
5. Yang, F.; Jin, Q.; He, Y.; Li, L.; Hou, Y. The complete genome of Enterovirus 71 China strain. Sci. China Ser. C Life Sci. 2001, 44, 178–183. [CrossRef] [PubMed]
6. Chen, S.C.; Chang, H.L.; Yan, T.R.; Cheng, Y.T.; Chen, K.T. An eight-year study of epidemiologic features of enterovirus 71 infection in Taiwan. Am. J. Trop. Med. Hyg. 2007, 77, 188–191. [PubMed]
7. Goto, K.; Sanefuji, M.; Kusuhara, K.; Nishimura, Y.; Shimizu, H.; Kira, R.; Torisu, H.; Hara, T. Rhombencephalitis and coxsackievirus A16. Emerg. Infect. Dis. 2009, 15, 1689–1691. [CrossRef] [PubMed]
8. Ang, L.W.; Koh, B.K.; Chan, K.P.; Chua, L.T.; James, L.; Goh, K.T. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001–2007. Ann. Acad. Med. Singapore 2009, 38, 106–112. [PubMed]
9. Robinson, C.R.; Doane, F.W.; Rhodes, A.J. Report of an outbreak of febrile illness with pharyngeal lesions and exanthem: Toronto, summer 1957; isolation of group A Coxsackie virus. Can. Med. Assoc. J. 1958, 79, 615–621. [PubMed]
10. Urquhart, G.E. A survey of coxsackie A16 virus antibodies in human sera. J. Hyg. 1984, 93, 205–212. [CrossRef] [PubMed]
11. Wang, C.Y.; Lu, F.L.; Wu, M.H.; Lee, C.Y.; Huang, L.M. Fatal coxsackievirus A16 infection. Pediatr. Infect. Dis. J. 2004, 23, 275–276. [CrossRef] [PubMed]
12. Wright, H.T., Jr.; Landing, B.H.; Lennette, E.H.; Mc, A.R. Fatal infection in an infant associated with Coxsackie virus group A, type 16. N. Engl. J. Med. 1963, 268, 1041–1044. [CrossRef] [PubMed]
13. Yip, C.C.; Lau, S.K.; Zhou, B.; Zhang, M.X.; Tsoi, H.W.; Chan, K.H.; Chen, X.C.; Woo, P.C.; Yuen, K.Y. Emergence of enterovirus 71 “double-recombinant” strains belonging to a novel genotype D originating from southern China: First evidence for combination of intratypic and intertypic recombination events in EV71. Arch. Virol. 2010, 155, 1413–1424. [CrossRef] [PubMed]
14. Chen, H.; Zhang, Y.; Yang, E.; Liu, L.; Che, Y.; Wang, J.; Zhao, H.; Tang, D.; Dong, C.; Yang, L., et al. The effect of enterovirus 71 immunization on neuropathogenesis and protein expression profiles in the thalamus of infected rhesus neonates. Virology 2012, 432, 417–426. [CrossRef] [PubMed]
15. Zhang, Y.; Zhu, Z.; Yang, W.; Ren, J.; Tan, X.; Wang, Y.; Mao, N.; Xu, S.; Zhu, S.; Cui, A., et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol. J. 2010, 7. [CrossRef] [PubMed]
16. Liang, Z.; Mao, Q.; Gao, F.; Wang, J. Progress on the research and development of human enterovirus 71 (EV71) vaccines. Front. Med. 2013, 7, 111–121. [CrossRef] [PubMed]
17. Choi, H.J.; Song, J.H.; Park, K.S.; Baek, S.H. In vitro anti-enterovirus 71 activity of gallic acid from Woodfordia fruticosa flowers. Lett. Appl. Microbiol. 2010, 50, 438–440. [CrossRef] [PubMed]
18. Liang, Z.; Wang, J. EV71 vaccine, an invaluable gift for children. Clin. Transl. Immunol. 2014, 3. [CrossRef] [PubMed]
19. Liu, Q.; Yan, K.; Feng, Y.; Huang, X.; Ku, Z.; Cai, Y.; Liu, F.; Shi, J.; Huang, Z. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine 2012, 30, 6642–6648. [CrossRef] [PubMed]
20. Mao, Q.; Li, N.; Yu, X.; Yao, X.; Li, F.; Lu, F.; Zhuang, H.; Liang, Z.; Wang, J. Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch. Virol. 2012, 157, 37–41. [CrossRef] [PubMed]
21. Chong, P.; Hsieh, S.Y.; Liu, C.C.; Chou, A.H.; Chang, J.Y.; Wu, S.C.; Liu, S.J.; Chow, Y.H.; Su, I.J.; Klein, M. Production of EV71 vaccine candidates. Hum. Vaccin. Immunother. 2012, 8, 1775–1783. [CrossRef] [PubMed]
22. Li, J.; Chang, J.; Liu, X.; Yang, J.; Guo, H.; Wei, W.; Zhang, W.; Yu, X.F. Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates. J. Gen. Virol. 2014, 95, 1083–1093. [CrossRef] [PubMed]
23. Reed, L.J.; Muench, H. A simple method of estimating fifity percent endpoints. Am. J. Hyg. 1938, 27, 493–497.
24. Wei, W.; Guo, H.; Li, J.; Ren, S.; Wei, Z.; Bao, W.; Hu, X.; Zhao, K.; Zhang, W.; Zhou, Y., et al. Circulating HFMD-associated coxsackievirus A16 is genetically and phenotypically distinct from the prototype CV-A16. PLoS ONE 2014, 9, e94746. [CrossRef] [PubMed]
25. Curry, S.; Fry, E.; Blakemore, W.; Abu-Ghazaleh, R.; Jackson, T.; King, A.; Lea, S.; Newman, J., Stuart, D. Dissecting the roles of VP0 cleavage and RNA packaging in picornavirus capsid stabilization: The structure of empty capsids of foot-and-mouth disease virus. J. Virol. 1997, 71, 9743–9752. [PubMed]
26. Chong, P.; Guo, M.S.; Lin, F.H.; Hsiao, K.N.; Weng, S.Y.; Chou, A.H.; Wang, J.R.; Hsieh, S.Y.; Su, I.J.; Liu, C.C. Immunological and biochemical characterization of coxsackie virus A16 viral particles. PLoS ONE 2012, 7, e49973. [CrossRef] [PubMed]
27. Blom, N.; Hansen, J.; Blaas, D.; Brunak, S. Cleavage site analysis in picornaviral polyproteins: Discovering cellular targets by neural networks. Protein Sci. 1996, 5, 2203–2216. [CrossRef] [PubMed]
28. Wu, C.N.; Lin, Y.C.; Fann, C.; Liao, N.S.; Shih, S.R.; Ho, M.S. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001, 20, 895–904. [CrossRef]
29. Liu, C.C.; Chou, A.H.; Lien, S.P.; Lin, H.Y.; Liu, S.J.; Chang, J.Y.; Guo, M.S.; Chow, Y.H.; Yang, W.S.; Chang, K.H., et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 2011, 29, 4362–4372. [CrossRef] [PubMed]
30. Chang, J.Y.; Chang, C.P.; Tsai, H.H.; Lee, C.D.; Lian, W.C.; Ih Jen, S.; Sai, I.H.; Liu, C.C.; Chou, A.H.; Lu, Y.J., et al. Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. Vaccine 2012, 30, 703–711. [CrossRef] [PubMed]
31. Hagiwara, A.; Tagaya, I.; Yoneyama, T. Epidemic of hand, foot and mouth disease associated with enterovirus 71 infection. Intervirology 1978, 9, 60–63. [CrossRef] [PubMed]
32. Iakovenko, M.L.; Korotkova, E.A. Evolution of vaccine poliovirus strains. Vopr. Virusol. 2008, 53, 45–48, following back cover. [PubMed]
33. Foo, D.G.; Alonso, S.; Chow, V.T.; Poh, C.L. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes. Infect. 2007, 9, 1299–1306. [CrossRef] [PubMed]
34. Vlecken, D.H.; Pelgrim, R.P.; Ruminski, S.; Bakker, W.A.; van der Pol, L.A. Comparison of initial feasibility of host cell lines for viral vaccine production. J. Virol. Methods 2013, 193, 28–41. [CrossRef] [PubMed]
35. Kalbfuss, B.; Wolff, M.; Morenweiser, R.; Reichl, U. Purification of cell culture-derived human influenza A virus by size-exclusion and anion-exchange chromatography. Biotechnol. Bioeng. 2007, 96, 932–944. [CrossRef] [PubMed]
36. Govorkova, E.A.; Murti, G.; Meignier, B.; de Taisne, C.; Webster, R.G. African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses. J. Virol. 1996, 70, 5519–5524. [PubMed]
37. Chen, C.W.; Lee, Y.P.; Wang, Y.F.; Yu, C.K. Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine. Vaccine 2011, 29, 2772–2776. [CrossRef] [PubMed]